KalVista Pharmaceuticals‘ investigational therapy KVD900 for the treatment of hereditary angioedema (HAE) rapidly reduces the activity of plasma…
Articles by Joana Carvalho, PhD
Prophylactic (preventative) treatment with Cinryze reduced the number and severity of attacks in young children with hereditary angioedema (HAE),…
Takhzyro (lanadelumb), an antibody already approved for routine prevention of hereditary angioedema (HAE) attacks in patients ages 12 and…
Angiotensin-converting enzyme (ACE) activity levels can vary among different donors of fresh frozen plasma (FFP) — commonly used for the treatment of…
A recently described mutation in the plasminogen (PLG) gene has been reported in an additional family in Germany with hereditary…
The three prophylactic medicines currently on the market for hereditary angioedema (HAE) — the C1 esterase inhibitors Cinryze and Haegarda, and Takzyhro…
Intestinal hereditary angioedema (HAE) should be considered as a possible cause of abdominal pain, even in patients with normal C1…
Despite being more prone to developing heart disease, patients with hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) show…
Ruconest (recombinant C1-inhibitor, rhC1-INH) and Firazyr (icatibant) are safe and effective approaches as first-line treatment for hereditary angioedema (HAE) attacks in…
The mother of a 28-year old pregnant woman suspected her daughter had hereditary angioedema after doing an internet search while the…